BerGenBio ASA

Oslo Stock Exchange BGBIO.OL

BerGenBio ASA Price to Earnings Ratio (P/E) on January 14, 2025: -1.61

BerGenBio ASA Price to Earnings Ratio (P/E) is -1.61 on January 14, 2025, a 59.76% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

BerGenBio ASA 52-week high Price to Earnings Ratio (P/E) is -0.74 on November 15, 2024, which is 54.38% above the current Price to Earnings Ratio (P/E).
BerGenBio ASA 52-week low Price to Earnings Ratio (P/E) is -169.84 on May 24, 2024, which is -10,429.03% below the current Price to Earnings Ratio (P/E).
BerGenBio ASA average Price to Earnings Ratio (P/E) for the last 52 weeks is -2.61.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Oslo Stock Exchange: BGBIO.OL

BerGenBio ASA

CEO	Mr. Martin Olin
IPO Date	April 7, 2017
Location	Norway
Headquarters	Jonas Lies vei 91
Employees	15
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Key trends

Past 5 years